Police are investigating five current and former AstraZeneca employees over infringement of data privacy laws and importing an unlicensed medicine, Bloomberg reports. The people being held are all Chinese citizens who marketed cancer drugs in AstraZeneca’s oncology division, according to people familiar with the matter. One probe is related to the company’s collection of patient data, and whether that infringed China’s data-privacy laws, while authorities are also looking into some of the individuals’ involvement in importing a liver cancer drug that hasn’t been approved for distribution in mainland China, the sources say. “We are aware a small number of our employees in China are under investigation and we have no further information to share at this point,” AstraZeneca said in a statement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- C4 Therapeutics appoints Stephen Fawell to board of directors
- Statement from President Biden on anti-obesity medications pricing
- Powell says ‘time has come’ for Fed to cut: Morning Buzz
- AstraZeneca Warns on Relocating UK Vaccine Manufacturing to US
- AstraZeneca warns it may move U.K. vaccine manufacturing to U.S., FT says